Challenges for model-based economic evaluations of postmenopausal osteoporosis interventions
- PMID: 11716188
- DOI: 10.1007/s001980170036
Challenges for model-based economic evaluations of postmenopausal osteoporosis interventions
Abstract
Assessing the cost-effectiveness of long-term treatment for osteoporosis requires use of mathematical models to estimate health effects and costs for competing interventions. The primary motivations for model-based analyses include the lack of long-term clinical trial outcome data and the lack of data comparing all relevant treatments within randomized clinical trials. We report on specific modeling challenges that arose in the development of a model of the natural history of postmenopausal osteoporosis that is suitable for assessing the cost-effectiveness of osteoporosis interventions among various population subgroups in diverse countries. These include choice of modeling changes in bone mineral density (BMD) or in fracture rate, definition of health states, modeling mortality and costs of long-term care following fracture, incorporation of health utility, and model validation. This report should facilitate future postmenopausal osteoporosis model development and provide insight for decision-makers who must evaluate model-based economic analyses of postmenopausal osteoporosis interventions.
Similar articles
-
Health-economic comparison of three recommended drugs for the treatment of osteoporosis.Int J Clin Pharmacol Res. 2004;24(1):1-10. Int J Clin Pharmacol Res. 2004. PMID: 15575171
-
Pharmacoeconomic analysis of osteoporosis treatment with risedronate.Int J Clin Pharmacol Res. 2003;23(4):93-105. Int J Clin Pharmacol Res. 2003. PMID: 15224498
-
Potential cost-effectiveness of denosumab for the treatment of postmenopausal osteoporotic women.Bone. 2010 Jul;47(1):34-40. doi: 10.1016/j.bone.2010.03.009. Epub 2010 Mar 18. Bone. 2010. PMID: 20303422
-
Primary care use of FRAX: absolute fracture risk assessment in postmenopausal women and older men.Postgrad Med. 2010 Jan;122(1):82-90. doi: 10.3810/pgm.2010.01.2102. Postgrad Med. 2010. PMID: 20107292 Review.
-
A review of the cost effectiveness of bisphosphonates in the treatment of post-menopausal osteoporosis in Switzerland.Appl Health Econ Health Policy. 2011 Nov 1;9(6):403-17. doi: 10.2165/11592210-000000000-00000. Appl Health Econ Health Policy. 2011. PMID: 21910511 Review.
Cited by
-
Multimorbidity in chronic disease: impact on health care resources and costs.Risk Manag Healthc Policy. 2016 Jul 5;9:143-56. doi: 10.2147/RMHP.S97248. eCollection 2016. Risk Manag Healthc Policy. 2016. PMID: 27462182 Free PMC article. Review.
-
Cost-effectiveness of the treatment and prevention of osteoporosis--a review of the literature and a reference model.Osteoporos Int. 2007 Jan;18(1):9-23. doi: 10.1007/s00198-006-0257-0. Epub 2006 Nov 9. Osteoporos Int. 2007. PMID: 17093892 Review.
-
Cost effectiveness of the German screen-and-treat strategy for postmenopausal osteoporosis.Pharmacoeconomics. 2008;26(6):513-36. doi: 10.2165/00019053-200826060-00005. Pharmacoeconomics. 2008. PMID: 18489201
-
A systematic review of models used in cost-effectiveness analyses of preventing osteoporotic fractures.Osteoporos Int. 2014 Jan;25(1):51-60. doi: 10.1007/s00198-013-2551-y. Epub 2013 Oct 24. Osteoporos Int. 2014. PMID: 24154803
-
Cost-effectiveness of strontium ranelate in the treatment of male osteoporosis.Osteoporos Int. 2013 Aug;24(8):2291-300. doi: 10.1007/s00198-013-2272-2. Epub 2013 Feb 1. Osteoporos Int. 2013. PMID: 23371359 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources